Amgen Inc (AMGN) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Total Assets Chart for Amgen Inc
Amgen Inc (AMGN) total assets for FY2025 were USD 90.6B, a -1.4% change from FY2024. Amgen Inc's total assets grew from USD 93.7M in 1985 to USD 90.6B in 2025 (96576.6% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 7.6%, 10-year CAGR of 2.4%, 20-year CAGR of 5.8%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $219.02B
- Implied Share Price
- $404.85
- Enterprise Value
- $253.16B
- Revenue (TTM)
- $38.09B
- EBITDA
- $17.57B
- Profit Margin
- 22.95%
- Trailing P/E
- 25.32
- Forward P/E
- 17.33
- Price/Book (MRQ)
- 22.62
- Price/Sales (TTM)
- 5.75
- EV/EBITDA
- 15.18
- EV/Revenue
- 6.80
- Dividend Yield
- 2.40%
- Book Value
- $21.62
- Free Cash Flow (FY2025)
- $8.10B
- Free Cash Flow Yield
- 3.70%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.